6.45
전일 마감가:
$6.48
열려 있는:
$6.48
하루 거래량:
40,204
Relative Volume:
0.03
시가총액:
$707.51M
수익:
-
순이익/손실:
$-167.48M
주가수익비율:
-3.3077
EPS:
-1.95
순현금흐름:
$-197.47M
1주 성능:
+2.06%
1개월 성능:
+2.38%
6개월 성능:
-49.88%
1년 성능:
-53.36%
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
명칭
Day One Biopharmaceuticals Inc
전화
650 484-0899
주소
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
DAWN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
DAWN
Day One Biopharmaceuticals Inc
|
6.455 | 707.51M | 0 | -167.48M | -197.47M | -1.95 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
444.71 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
527.26 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
317.64 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
561.76 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.57 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-10-09 | 재확인 | Needham | Buy |
2024-08-01 | 업그레이드 | BofA Securities | Underperform → Buy |
2024-04-24 | 재확인 | Needham | Buy |
2023-04-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
2023-02-08 | 개시 | CapitalOne | Overweight |
2023-02-03 | 개시 | Oppenheimer | Perform |
2022-12-15 | 개시 | H.C. Wainwright | Buy |
2022-12-14 | 개시 | Needham | Buy |
2022-12-05 | 개시 | Goldman | Buy |
2022-12-01 | 개시 | BofA Securities | Buy |
모두보기
Day One Biopharmaceuticals Inc 주식(DAWN)의 최신 뉴스
Day 8 of Loss Streak for Day One Biopharmaceuticals Stock with -11% Return (vs. -49% YTD) [6/18/2025] - Trefis
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of “Buy” by Brokerages - Defense World
Pallas Capital Advisors LLC Takes Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Bank of America Corp DE Has $260,000 Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Where are the Opportunities in (DAWN) - news.stocktradersdaily.com
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Transcript : Day One Biopharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - MarketScreener
Day One Appoints Michael Vasconcelles As Head Of Research And Development - MarketScreener
Day One Biopharmaceuticals (DAWN) Welcomes New R&D Leader | DAWN Stock News - GuruFocus
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development - GlobeNewswire
Day One Taps ImmunoGen Executive to Lead R&D: 25-Year Oncology Expert Joins Cancer Drug Developer - Stock Titan
H.C. Wainwright Maintains Buy Rating on Day One Biopharmaceuticals (DAWN), Keeps PT - MSN
Ameriprise Financial Inc. Decreases Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Squarepoint Ops LLC Acquires New Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
JonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA Approval - Insider Monkey
Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301 - Seeking Alpha
Nuveen Asset Management LLC Lowers Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by Millennium Management LLC - Defense World
ProShare Advisors LLC Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,894 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Cetera Investment Advisers Has $400,000 Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
36,685 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by BNP Paribas Financial Markets - Defense World
D. E. Shaw & Co. Inc. Increases Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of “Buy” from Brokerages - Defense World
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth - Yahoo Finance
Northern Trust Corp Grows Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day one Biopharmaceuticals officer sells $24,574 in stock By Investing.com - Investing.com Nigeria
Day one Biopharmaceuticals officer sells $24,574 in stock - Investing.com
Day One Biopharmaceuticals Executives Sell Shares to Cover Tax Liabilities - TradingView
Day one biopharmaceuticals highlights OJEMDA revenue growth and pipeline progress in Q1 2025 - MSN
Day One Biopharmaceuticals Insider Lowered Holding By 20% During Last Year - simplywall.st
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stake Decreased by Voya Investment Management LLC - Defense World
Transcript : Day One Biopharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Is Day One Biopharmaceuticals, Inc. (DAWN) the Best Low Priced Biotech Stock to Buy Now? - MSN
10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey
Trend Tracker for (DAWN) - news.stocktradersdaily.com
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down – Here’s What Happened - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Research Analysts Issue Forecasts for DAWN Q2 Earnings - Defense World
Needham & Company LLC Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $27.00 - Defense World
Research Analysts Set Expectations for DAWN Q2 Earnings - Defense World
Is Day One Biopharmaceuticals, Inc. (DAWN) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey
Analysts Issue Forecasts for DAWN Q1 Earnings - Defense World
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Earnings Beat - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Mariner LLC - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 12-Month Low Following Analyst Downgrade - Defense World
Day One Biopharma’s Earnings Call Highlights Growth - TipRanks
Day One Biopharmaceuticals (DAWN) Target Price Adjusted to $26 | DAWN Stock News - GuruFocus
Needham Adjusts Price Target for DAWN to $27, Maintains Buy Rati - GuruFocus
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q1 2025 Earnings Call Transcript - Insider Monkey
Day One Biopharmaceuticals Inc (DAWN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Day One Biopharmaceuticals Inc 주식 (DAWN) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Dubow Adam | GENERAL COUNSEL |
May 16 '25 |
Sale |
6.26 |
4,552 |
28,486 |
47,136 |
York Charles N II | COO, CFO AND SECRETARY |
May 16 '25 |
Sale |
6.26 |
4,282 |
26,796 |
265,231 |
Bender Jeremy | CHIEF EXECUTIVE OFFICER |
May 16 '25 |
Sale |
6.26 |
13,964 |
87,385 |
145,737 |
자본화:
|
볼륨(24시간):